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Background: This study updated our knowledge of UK primary care neuropathic pain incidence rates and
prescribing practices.
Methods: Patients with a first diagnosis of post-herpetic neuralgia (PHN), painful diabetic neuropathy (PDN) or
phantom limb pain (PLP) were identified from the General Practice Research Database (2006 – 2010) and incidence
rates were calculated. Prescription records were searched for pain treatments from diagnosis of these conditions
and the duration and daily dose estimated for first-line and subsequent treatment regimens. Recording of
neuropathic back and post-operative pain was investigated.
Results: The study included 5,920 patients with PHN, 5,340 with PDN, and 185 with PLP. The incidence per 10,000
person-years was 3.4 (95% CI 3.4, 3.5) for PHN; and 0.11 (95% CI 0.09, 0.12) for PLP. Validation of the PDN case
definition suggested that was not sensitive. Incident PHN increased over the study period. The most common
first-line treatments were amitriptyline or gabapentin in the PDN and PLP cohorts, and amitriptyline or co-codamol
(codeine-paracetamol) in PHN. Paracetamol, co-dydramol (paracetamol-dihydrocodeine) and capsaicin were also
often prescribed in one or more condition. Most first-line treatments comprised only one therapeutic class. Use of
antiepileptics licensed for neuropathic pain treatment had increased since 2002–2005. Amitriptyline was the only
antidepressant prescribed commonly as a first-line treatment.
Conclusion: The UK incidence of diagnosed PHN has increased with the incidence of back-pain and post-operative
pain unclear. While use of licenced antiepileptics increased, prescribing of therapy with little evidence of efficacy in
neuropathic pain is still common and consequently treatment was often not in-line with current guidance.
Keywords: Neuropathic pain, Incidence, Post-herpetic neuralgia, Painful diabetic neuropathy, Phantom limb pain,
Treatment, Antidepressant, Antiepileptic, Primary careBackground
A fifth of adults in Europe report moderate or severe
chronic pain with 2% managed by a specialist [1].
Neuropathic pain is defined as pain arising as a direct
consequence of a lesion or a disease affecting the so-
matosensory system [2]. The prevalence of pain of
predominantly neuropathic origin has been reported
as 7–8% in French and UK surveys [3,4], and is more in-
tense in comparison with chronic pain without neuropa-
thic characteristics [4]. The incidence of any neuropathic* Correspondence: gillian_hall@gchall.demon.co.uk
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reproduction in any medium, provided the orpain has been reported as 0.8% per annum in a Dutch pri-
mary care database [5], while two previous UK studies
based on electronic primary care records showed that the
incidence of both post-herpetic neuralgia and phantom
limb pain had been decreasing, while incident painful
diabetic neuropathy remained stable (1992 to 2005) [6,7].
The rate of diagnosed painful diabetic neuropathy may
have subsequently increased as UK primary care physi-
cians are now encouraged to ask diabetic patients about
neuropathic symptoms [8].
A 2006 European task force on pharmacological treat-
ment of neuropathic pain reported that treatment
remained unsatisfactory despite a substantial increase in. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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dence for the efficacy of tricyclic antidepressants, the
antiepileptic drugs gabapentin, pregabalin and opioids (in
post-herpetic neuralgia and painful polyneuropathies),
with some evidence on the efficacy of topical lidocaine
(in post-herpetic neuralgia) and the antidepressants,
venlafaxine and duloxetine (in painful polyneuropathies)
[10]. In UK primary care between 1999–2002 and 2002–
2005, treatment of neuropathic pain conditions shifted
from predominantly non-opioid analgesics towards tricyc-
lic antidepressants and antiepileptics [6,7]. That change
may be due to a combination of substantial increase in
evidence, education and the introduction and marketing
of drugs licensed for use in this indication.
Neuropathic back pain and post-operative pain other
than phantom limb pain were not studied in the previ-
ous UK primary care database analyses, as the identifica-
tion of these less well defined neuropathic pain
conditions was expected to be more difficult from a pri-
mary care database. However, these conditions affect
large populations. The adult annual rate for consulting
general practice for back pain is 6.4% [11], of which 16%
may have possible neuropathic pain [12]. Post-operative
pain is also common, although incidence rates vary be-
tween studies. For example, women who undergo breast
surgery are reported to experience chronic chest wall,
breast, or scar pain (range, 11–57%), phantom breast
pain (13–24%), and arm and shoulder pain (12–51%)
while the mean incidence of chronic pain after inguinal
hernia surgery was estimated as 11.5% [13].
The objectives of this study were to update the inci-
dence rates and prescribing practices for post-herpetic
neuralgia, phantom limb pain and painful diabetic neur-
opathy in UK primary care and to report any time
trends, and to examine the recording and treatment of
neuropathic back pain and post-operative pain.
Methods
Data source
The source population and prescribing data were re-
trieved from the General Practice Research Database
(GPRD). The GPRD is an observational database
containing information collected in computerised pri-
mary care practices throughout the UK. Details of demo-
graphics, primary care diagnoses and prescription
treatment are routinely recorded against date in individ-
ual patient records. Details of referrals, secondary care
diagnoses and deaths are also captured because of the
structure of the UK National Health Service. Major
events from before computerisation are added retro-
spectively. Data on preventive medicine can also be
recorded. Medical events are automatically coded at
entry using the Read coding system [14]. Each patient
on GPRD is given an ‘up to standard’ date when theirrecord is considered to be of sufficient quality for re-
search. A total of 531 practices were included in the
study. The protocol was approved by the GPRD scien-
tific and ethics committee.
Cohort definitions
The study population comprised all patients who were
permanently registered at a GPRD practice at any time
in the study period, from 1st January 2005 to 31st De-
cember 2010. Five neuropathic pain cohorts (post-her-
petic neuralgia, painful diabetic neuropathy, phantom
limb pain, neuropathic back pain and neuropathic post-
operative pain) were identified from this study popula-
tion by searching individual patient records for either a
single specific Read code, or a combination of Read and
therapy codes as specified in a case definition. Post-
herpetic neuralgia was defined as a specific code for
post-herpetic neuralgia, or a code for acute zoster plus
either a code for neuropathy, or neuropathic pain, be-
tween three and six months after the first acute zoster
entry. Phantom limb pain (PLP) was defined as a specific
code, or a code for amputation plus either a code for
neuropathy or neuropathic pain between three and
twenty-four months after the first amputation code. The
painful diabetic neuropathy cohort included patients
with a specific code for painful diabetic neuropathy;
those with a code for diabetes and a general code for
neuropathic pain and a third group with a code for dia-
betic neuropathy (or diabetes and neuralgia) with a pre-
scription for a neuropathic pain treatment which was
initiated within 28 days of the date of the neuropathy/
neuralgia code.
There is no specific code for neuropathic back pain
in the Read dictionary. The condition was defined as
a code for back pain plus either a code for neuropathy
or neuropathic pain within 28 days, or a code for
radiculopathy or back pain with a specific neuropathic
pain treatment (rather than general pain) initiated within
28 days of the back pain date. To identify patients with
neuropathic post-operative pain preliminary database
searches looked for patients with codes for surgery
followed by a record of post-operative pain, or surgery
plus either a code for neuropathic pain, or neuropathy
or persistent pain and a prescription for a specific
neuropathic pain treatment (rather than general pain)
initiated within 28 days of the pain record date. Few pa-
tients were found to meet these criteria, so to investigate
the recording of this condition, patients with a code for
breast or hernia surgery were identified as the preva-
lence of pain has been reported in this group [13]. For
this post-operative sub-group, records in the three to six
months after surgery were searched to identify patients
with a code for neuropathic pain, a code for post-
operative pain plus a code for neuropathy within 28 days,
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prescription for a specific neuropathic pain treatment
(rather than general pain) initiated within 28 days of the
neuropathy/pain code.
The cohort entry date for each patient was the date of
the first Read code for the specific condition (phantom
limb pain, painful diabetic neuropathy or post-herpetic
neuralgia), neuropathic pain, neuropathy, neuralgia, or
post-operative pain in the case definition. Prevalent
cases with a cohort entry date before 1st January 2006
were excluded. Patients could be included in more than
one cohort, but not in both phantom limb pain and
post-operative pain. A period of observation was set for
each subject with a start date of 1st January 2005 or, if
later, the date that the patient record was suitable for re-
search plus twelve months. The twelve months was
added to allow time for the recording of prevalent con-
ditions before the study started. The end date was the
first of the following: the end of the study period, death,
transfer-out of the practice, or the final data collection.
Validation of diagnosis
Questionnaires were sent to the general practitioners
(GPs) of a random sample of patients to confirm the
diagnosis. The sample comprised 108 patients with post-
herpetic neuralgia and 54 patients within the study def-
inition of painful diabetic neuropathy. An additional
group of 52 questionnaires tested for false negatives
among those patients whose records did not meet the
case definition but who did have a record of diabetes
and treated neuropathy; for example when a diabetic pa-
tient had peripheral neuropathy but was already on pre-
scription treatment for an analgesic at the time of the
first mention of peripheral neuropathy.
Prescription neuropathic pain therapy
A neuropathic pain treatment was defined as a prescrip-
tion for an analgesic (excluding aspirin 100 mg or less),
an anaesthetic (oral, dermal or intravenous), an antiepi-
leptic (with no history of epilepsy), or an antidepressant.
Therapeutic class was based on the British National
Formulary (BNF) [15]; antiepileptics (BNF 4.8.1), anti-
depressants (BNF 4.3 in total and divided into 4.3.1
and other), analgesics, (BNF 4.7.1 non-opioid analge-
sics and 4.7.2 opioid analgesics), rubefacients - capsai-
cin (BNF 10.3.2), local anaesthesia including lidocaine
hydrochloride (BNF 15.2) and other. Specific neuropa-
thic pain treatments were those antiepileptics, antidepre-
ssants and opioids commonly used for neuropathic pain
(Additional file 1).
Treatment patterns
The details of prescriptions for neuropathic pain treat-
ments were identified for the cohorts. For post-herpeticneuralgia, painful diabetic neuropathy and phantom limb
pain the first-line treatment was defined as a neuro-
pathic pain treatment started within 28 days of the co-
hort entry date. The case definitions for neuropathic
back pain and post-operative pain included only those
treatments specifically recommended or indicated in
neuropathic pain which might be second-line treat-
ments. Earlier prescribing was included in the treatment
analysis in order to include first-line treatment with less
specific agents. The first-line treatment for neuropathic
back pain was therefore defined as the first neuropathic
pain treatment in a treatment episode that spanned the
cohort entry date, but did not start before the back pain
or radiculopathy code, or that started in the 28 days
after the back pain or radiculopathy code.
Daily dose was estimated from the details on the pre-
scription and the duration of each prescription was esti-
mated from the daily dose and number of items
prescribed. When a prescription described a dose titra-
tion, then the final dose was included. When the dur-
ation could not be calculated from details on a
prescription, it was assumed to last 28 days. If more than
one therapy was prescribed on the same day then the
first-line treatment was considered to be the combin-
ation of these therapies. If more than one therapy was
prescribed, but on different days, the first-line treatment
regimen included only items on the first prescription.
Duration of the first-line treatment was the sum of the
individual prescription durations until discontinuation,
or prescription, of one or more treatments. A second-
line treatment regimen started when any change was
made to the original regimen without a break in all
treatment as a break in treatment was assumed to indi-
cate a new episode of pain. The change could be pre-
scription of a new treatment or discontinuation of part
of the first-line treatment. A therapy was considered to
have been discontinued when no additional prescription
was issued within 62 days of the end of the last prescrip-
tion. Third-line treatment was defined in the same
way as any addition or discontinuation without a break
in treatment.
Analysis
The incidence per person-years observation for 2006 to
2010 was estimated for post-herpetic neuralgia, phantom
limb pain and painful diabetic neuropathy. A rate (rather
than incidence) of identified new cases of neuropathic
back pain was estimated as the case definition for this
condition was not specific. Those with a first record of
their neuropathic pain dated during their period of ob-
servation were counted as incident cases. The denomin-
ator (person-years observation) was the sum of the
difference between the start date plus one year and end
date for each patient. The age and sex distribution at
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1st July of the recorded year of birth. Incidences were
standardised to the 2010 UK age-sex distribution [16].
Descriptive analyses reported the number of patients
with an first-line treatment identified, the treatments
prescribed (including number and type of therapy and
mean duration) and the percentage of use as first, sec-
ond and third line therapy for treatments prescribed to
more than 100 patients at any stage. The analysis
was completed by condition for patients with at least
18 months prescribing data after the cohort entry
date to provide sufficient prescribing history. The num-
ber of patients with each daily dosing regimen was
counted by year for all first prescriptions for gabapentin
or pregabalin.Results
Incidence
The study cohorts included 5,920 patients with post-
herpetic neuralgia, 5,340 with painful diabetic neur-
opathy, 185 with phantom limb pain and 90,941 with
neuropathic back pain. This provided annual incidence
rates per 10,000 population of 3.4 (95% Confidence in-
tervals (CI) 3.4, 3.5), for post-herpetic neuralgia, 3.1
(95%CI 3.0, 3.2) for painful diabetic neuropathy and 0.1
(95%CI 0.09, 0.12), for phantom limb pain. When
standardised to 2010 UK age and sex distribution, the
annual incidence per 10,000 population were 3.0 (95%CI
3.0, 3.1) for post-herpetic neuralgia, 2.8 (95%CI 2.7, 2.8)
for painful diabetic neuropathy and 0.11 (95%CI 0.09,
0.12) for phantom limb pain. The incidence of these
three conditions increased with age (Table 1). Phantom
limb pain was more common in men than women, while
post-herpetic neuralgia was more common in women.
The incidence of post-herpetic neuralgia and painful
diabetic neuropathy increased over the study period
(Figure 1). The mean annual number of patients with in-
cident events within our case definition of neuropathic
back pain was 18,188, increasing over the study period
from 49 to 62 per 10,000 population, per annum (mean
53). Despite widening the original case definition, only
49 patients were identified as having post-operative
neuropathic pain after either breast or hernia surgery.
The treatment analysis for this group is therefore
not reported.Validation of incidence
The GP questionnaire showed a positive predictive value
of 91% for post-herpetic neuralgia (n = 86, 80% response)
and 56% for painful diabetic neuropathy (n = 48, 89%
response). In those patients who did not meet the full
case definition for painful diabetic neuropathy 7% were
identified as false negatives (n = 45, 87% response).Treatment
Across the study conditions, between 80 and 87% of pa-
tients had an available follow-up period of 18 months
and so were included in the prescription treatment ana-
lysis (Table 2). The number with a first-line prescribed
therapy identified ranged from 59% with phantom limb
pain, to 100% with neuropathic back pain. A first-line
therapy could have been missed in patients with antiepi-
leptics and epilepsy, or if treatment was started more
than 28 days before the date of the first record of the
condition. The mean duration of the first therapy ranged
from 48 to 121 months between conditions, but there
was wide variation (Table 2). The majority of patients
were prescribed one item initially. The most common
first-line treatment was amitriptyline in post-herpetic
neuralgia and the painful diabetic neuropathy cohort,
gabapentin in phantom limb pain and tramadol in
neuropathic back pain.
An antidepressant or an antiepileptic was prescribed
as part of a first-line treatment for 57.0% of post-
herpetic neuralgia patients, 70.5% of the painful dia-
betic neuropathy cohort and 61.1% of the phantom
limb pain cohort. Analgesics alone (opioid +/− non-
opioid) were prescribed first-line for 36.3% of patients
with post-herpetic neuralgia, 25.4% of patients in the
painful diabetic neuropathy cohort and 37.7% of pa-
tients with phantom limb pain (Table 3). An opioid, or
a combination of opioid and non-opioid analgesic, was
prescribed most frequently as a first-line treatment
for neuropathic back pain, 64.0% of cases (Table 3). An-
tiepileptics were the most common therapeutic cat-
egory in first-line treatments prescribed for phantom
limb pain. Most first-line treatments included only one
therapeutic class.
The total number of patients who received a prescrip-
tion for either gabapentin or pregabalin increased over
the study period (Table 4). Gabapentin was prescribed
most frequently with a dosage regimen of three times
per day, whereas pregabalin was prescribed most fre-
quently for twice a day use. However, no clear daily
dosage was recorded in 43.9% of those prescribed
gabapentin and 27.8% prescribed pregabalin.
With most therapies, higher daily doses were used
as second- or third-line treatment. The opioids mor-
phine, buprenorphine, dihydrocodeine (not in combin-
ation with other analgesics), oxycodone, fentanyl, and
meptazinol were usually prescribed following another
first-line regimen as were nefopam, duloxetine, lido-
caine patches and lower doses of mirtazapine. Lido-
caine patches were infrequently used in post-herpetic
neuralgia and duloxetine and venlafaxine were pre-
scribed to less than 100 patients (<2%) as a first-line
treatment in the painful diabetic neuropathy cohort
(Additional file 2).
Table 1 Annual incidence of neuropathic pain conditions per 10,000 by age and sex
Female Male
Incidence (95%CI) Incidence (95%CI)
Post-herpetic neuralgia All ages 4.3 (4.2-4.4) 2.6 (2.5-2.7)
0 - 14 0.1 (0.1-0.2) 0.1 (0.0-0.1)
15 - 29 0.6 (0.4-0.7) 0.2 (0.2-0.3)
30 - 44 1.0 (0.8-1.1) 0.5 (0.4-0.6)
45 - 59 3.0 (2.8-3.3) 1.9 (1.7-2.1)
60 - 74 9.2 (8.7-9.7) 6.6 (6.2-7.1)
≥75 16.6 (15.8-17.5) 13.6 (12.7-14.6)
Phantom limb pain All ages 0.1 (0.0-0.1) 0.2 (0.1-0.2)
0 - 14 0 0
15 - 29 <0.1 (0.0-0.1) <0.1 (0.0-0.1)
30 - 44 <0.1 (0.0-0.1) 0.1 (0.1-0.2)
45 - 59 0.1 (0.0-0.1) 0.1 (0.1-0.2)
60 - 74 0.1 (0.1-0.2) 0.4 (0.3-0.5)
≥75 0.1 (0.1-0.2) 0.7 (0.5-0.9)
Painful diabetic neuropathy cohort All ages 2.9 (2.8-3.0) 3.3 (3.2-3.4)
0 - 14 0 <0.1 (0.0-0.1)
15 - 29 0.2 (0.1-0.3) 0.1 (0.0-0.1)
30 - 44 0.8 (0.7-1.0) 0.9 (0.8-1.0)
45 - 59 3.0 (2.8-3.3) 3.7 (3.4-4.0)
60 - 74 7.0 (6.6-7.5) 9.2 (8.7-9.7)
≥75 8.3 (7.7-8.9) 10.8 (10.0-11.7)
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Post-herpetic neuralgia and phantom limb pain
This study found an annual incidence per 10,000
person-years adjusted to the 2010 UK age and sex distri-
bution of 3.0 for post-herpetic neuralgia and 0.1 for
phantom limb pain, with rates increasing for post-
herpetic neuralgia during the study period (Figure 1).
This study updates two previous similar incidence esti-
mates based on UK primary care electronic records be-
tween 1992 and 2005 [6,7]. Post-herpetic neuralgia
decreased between the two earlier study periods from
4.0 (1992–2002) to 2.8 (2002–2005), compared to 3.4
per 10,000 in the current study. When the two most re-
cent studies were age-sex standardised to 2010 levels, a
small rise from 2.7 to 3.0 per 10,000 was seen between
2002–2005 and the current study. There were few cases
of phantom limb pain with 2010 age-sex adjusted inci-
dences per 10,000 person-years of 0.11 (95%CI 0.07,
0.17) in the current study compared to 0.08 (95%CI
0.04, 0.17) in 2002–2005 suggesting little change.
An annual age-sex adjusted incidence of painful dia-
betic neuropathy of 3.1 per 10,000 was found. However,
the results of the GP questionnaire indicates that this is
an over estimate as only 56% of those identified had a
final diagnosis of painful diabetic neuropathy. A reviewof the codes and treatment patterns of those with and
without a final diagnosis of painful diabetic neuropathy
showed that recording was similar in both groups with
none using a specific Read code. Consequently it was
not possible to alter the case definition to improve sensi-
tivity. It is feasible that the introduction of the UK Qual-
ity and Outcomes Framework (QoF) in 2004 resulted in
GPs increasingly making a preliminary diagnosis of pain-
ful diabetic neuropathy which is then not confirmed at
secondary care. Within this government initiative, pri-
mary care physicians are paid to review chronically ill
patients, including diabetic patients, with some payment
dependent on evidence of checking for complications
such as neuropathy. A record of neuropathy testing in-
creased sharply around the time of QoF introduction
with one study reporting a rise from 8% of diabetic pa-
tient records in the 15 months to April 2003 to 66% in
the 15 months to April 2005 with rates of recording
then levelling [17]. There has also been increased aware-
ness of neuropathic pain with the introduction and mar-
keting of new licensed treatments and publication of
treatment guidelines. This may have resulted in an in-
crease in both the diagnosis of neuropathic pain and the
use of treatments such as amitriptyline and gabapentin










2006 2007 2008 2009 2010
Post herpetic neuralgia Phantom limb pain
Painful diabetic neuropathy
Figure 1 The annual incidence of neuropathic pain conditions
(per 10,000 person-years) between 2006 and 2010.
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our definition) increased over the study period from an
annual incidence of 2.7 to 3.8 per 100,000 population
(Figure 1).
Most other studies assessing the incidence of these
neuropathic pain conditions have been within specific
sub-populations, such as people with acute herpes zos-
ter, diabetes or post-amputation. One earlier UK general
population study reported incidence per 10,000 popula-
tion of 5.4 for diabetic polyneuropathy and 1.1 for post-
herpetic neuralgia [18]. A study of shingles in patients
aged 50 years or more (2000–2006) found that 19.5%
had post-herpetic neuralgia at one month and 13.7% atTable 2 First-line treatment by pain condition (2006–2010)
Post-herpetic
neuralgia
Totala (% of cohort) 4,725 (79.8)
Number with a treatment (% total in
analysis)
3,831 (81.1)
Duration of treatment (days), mean (±SD) b 48 (115)
Items prescribed on initial prescription as% of those treated
1 item 65.0
2 items 28.7
3 or more items 6.4











awith incident disease plus 18 months record. bignoring titration of dose. SD, standthree months which would give incidence rates per
10,000 population of 10.2 at one month and 7.2 at three
months, which is in-line with this study’s findings given
the older population [19].
Treatment
Amitriptyline was the most commonly prescribed treat-
ment in a first-line therapy for the post-herpetic neural-
gia and painful diabetic neuropathy cohorts and the
second most frequent after gabapentin in phantom limb
pain. Gabapentin was also frequently prescribed as a
first-line treatment in the painful diabetic neuropathy
cohort and in post-herpetic neuralgia, with the use of
both gabapentin and pregabalin increasing over the
study period. This demonstrates a maintained shift from
predominant use of opioid and non-opioid analgesics in
the late 1990’s to use of tricyclic antidepressants and an-
tiepileptics, with initiation of these therapies now evi-
dent in primary, rather than secondary, care. This shift
appears to be the case across conditions as our painful
diabetic neuropathy cohort will have included other
neuropathic pain. Compared to the 2002–2005 data,
amitriptyline remains a common first-line treatment al-
though use has decreased in post-herpetic neuralgia and
phantom limb pain (2002–2005 : 2006–2010, 50% : 39%
in post-herpetic neuropathy and 41% : 21% in phantom
limb pain). Antiepileptic prescribing has moved from






4,317 (80.1) 153 (82.7) 78,693 (86.5)
3,513 (81.4) 90 (58.8) 78,417 (99.6)




ns, n (% treated)
amitriptyline gabapentin tramadol
1362 (38.8) 22 (24.4) 26,778 (34.1)
gabapentin amitriptyline amitriptyline
539 (15.3) 19 (21.1) 17,093 (21.8)
co-codamol paracetamol co-codamol
332 (9.5) 12 (13.3) 16,198 (20.7)
pregabalin pregabalin paracetamol
315 (9.0) 12 (13.3) 6750 (8.6)
paracetamol tramadol co-dydramol
264 (7.5) 7 (7.8) 5320 (6.8)
ard deviations.









n (%) n (%) n (%) n (%)
Total treated 3,831 (100) 3,513 (100) 90 (100) 78,417 (100)
Anaesthetics alone 4 (<0.1) 1 (<0.1) 0 3 (<0.1)
Antiepileptics alone 526 (13.7) 892 (25.4) 27 (30.0) 3,030 (3.9)
Non-opioid analgesics alone 223 (5.8) 225 (6.4) 10 (11.1) 3,622 (4.6)
Opioid analgesics alone 296 (7.7) 254 (7.2) 17 (19.0) 25,903 (33.0)
Other antidepressants alone 23 (0.6) 79 (2.2) 0 3,007 (3.8)
Rubefacients alone 220 (5.7) 142 (4.0) 1 (1.1) 666 (0.8)
Tricyclic antidepressants alone 1,223 (31.9) 1,328 (37.8) 16 (17.8) 13,901 (17.7)
Anaesthetics + tricyclic antidepressants 1 (<0.1) 0 0 0
Antiepileptics + non-opioid analgesics 9 (0.2) 9 (0.3) 1 (1.1) 104 (0.1)
Antiepileptics + opioid analgesics 19 (0.5) 19 (0.5) 3 (3.3) 224 (0.3)
Antiepileptics + other antidepressants 4 (0.1) 5 (0.1) 1 (1.1) 84 (0.1)
Antiepileptics + rubefacients 13 (0.3) 9 (0.3) 0 9 (<0.1)
Antiepileptics + tricyclic antidepressants 10 (0.3) 7 (0.2) 2 (2.2) 100 (0.1)
Non-opioid analgesics + other
antidepressants
0 0 0 133 (0.2)
Non-opioid analgesics + rubefacients 5 (0.1) 1 (<0.1) 0 44 (<0.1)
Non-opioid analgesics + tricyclic
antidepressants
34 (0.9) 16 (0.5) 0 567 (0.7)
Opioid analgesics + non-opioid analgesics 873 (22.8) 412 (11.7) 7 (7.8) 20,651 (26.3)
Opioid analgesics + other antidepressants 0 3 (0.1) 2 (2.2) 358 (0.5)
Opioid analgesics + rubefacients 7 (0.2) 2 (0.1) 0 26 (<0.1)
Opioid analgesics + tricyclic antidepressants 54 (1.4) 21 (0.6) 0 1,147 (1.5)
Other antidepressants + tricyclic
antidepressants
1 (<0.1) 4 (0.1) 0 120 (0.2)
Rubefacients + tricyclic antidepressants 55 (1.4) 11 (0.3) 0 20 (<0.1)
1 therapeutic class 2,515 (65.6) 2.921 (83.1) 71 (78.9) 50,132 (63.9)
2 therapeutic classes 1,085 (28.3) 519 (14.8) 16 (17.8) 23,590 (30.1)
3 or more therapeutic classes 231 (6.0) 73 (2.1) 3 (3.3) 4,695 (6.0)
Antidepressant or antiepileptic 2184 (57.0) 2,475 (70.5) 55 (61.1) 27,319 (34.8)
Analgesic alone (opioid or non-opioid) 1,392 (36.3) 891 (25.4) 34 (37.8) 50,176 (64.0)
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pain (2002–2005 versus 2006–2010: 17% versus 38%).
Opioid use has increased slightly with tramadol now
prescribed more often than co-codamol (codeine phos-
phate and paracetamol) as a first-line treatment in
phantom limb pain. The changes may be due to a com-
bination of an increasing evidence of efficacy in both
placebo-controlled and head-to-head trials, education
and marketing.
The prescribing analysis period of 2006–2010 was,
for the most part, prior to the publication of the current
UK and European recommendations on neuropathic
pain treatment, although after the publication of key
randomised controlled trials for the newer antiepileptics,antidepressants and opioids in neuropathic pain [10,20].
The prescribing of antiepileptics and antidepressants
as first-line treatment is consistent with the current
recommendations and the shift from carbamazepine to
gabapentin, or pregabalin is supported by evidence from
clinical trials. The European Federation of Neurological
Sciences (EFNS) 2010 guidelines recommends gabap-
entin, pregabalin, lidocaine plasters and tricyclic anti-
depressants in post-herpetic neuralgia and duloxetine,
gabapentin, pregabalin, tricyclic antidepressants and ven-
lafaxine in painful diabetic neuropathy [10]. The 2010
UK National Institute for Clinical Excellence (NICE)
guidelines recommends first-line treatment with dulo-
xetine or, if contraindicated, amitriptyline for painful
Table 4 Daily dosing regimen by year for all first prescriptions of gabapentin or pregabalin
Drug Year n OD BD TDS Other PRN Unknown
gabapentin 2006 4,210 279 (6.6) 175 (4.2) 1,812 (43.0) 44 (1.0) 236 (5.6) 1,664 (39.5)
2007 5,433 307 (5.7) 178 (3.3) 2,392 (44.0) 29 (0.5) 217 (4.0) 2,310 (42.5)
2008 6,083 333 (5.5) 184 (3.0) 2,626 (43.2) 46 (0.8) 213 (3.5) 2,681 (44.1)
2009 6,938 374 (5.4) 181 (2.6) 3,073 (44.3) 38 (0.5) 217 (3.1) 3,055 (44.0)
2010 7,207 382 (5.3) 154 (2.1) 3,059 (42.4) 27 (0.4) 179 (2.5) 3,406 (47.3)
pregabalin 2006 2,719 139 (5.1) 1,336 (49.1) 453 (16.7) 10 (0.4) 79 (2.9) 702 (25.8)
2007 2,979 147 (4.9) 1,509 (50.7) 488 (16.4) 6 (0.2) 68 (2.3) 761 (25.5)
2008 3,652 236 (6.5) 1,690 (46.3) 608 (16.6) 18 (0.5) 94 (2.6) 1,006 (27.5)
2009 4,333 275 (6.3) 2,023 (46.7) 706 (16.3) 15 (0.3) 87 (2.0) 1,227 (28.3)
2010 5,416 328 (6.1) 2,518 (46.5) 822 (15.2) 14 (0.3) 116 (2.1) 1,618 (29.9)
OD once daily, BD twice daily, TDS three times daily, PRN as required.
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first-line treatment options for other neuropathic pain
[20]. Duloxetine, venlafaxine (painful diabetic neuropathy)
and topical lidocaine (post-herpetic neuralgia) use was
uncommon in this study although there was evidence
of efficacy before the study period [10] and all three
treatments were included in guidelines as second-line
interventions in 2006 [9]. They were not recommen-
ded as first-line agents until 2010 [10,20]. The com-
mon use of paracetamol first-line in the painful diabetic
neuropathy cohort is consistent with guidance in type 1
diabetes from 2004 to 2010 [21] although this recom-
mendation has been superseded. GPs may have follo-
wed type 1 guidance until specific guidance for type 2
diabetes was available from NICE in 2008 [22]. Para-
cetamol is currently recommended for use as a first-
line treatment in combination with tramadol in neuro-
pathic pain with acute exacerbations and this may partially
explain the common use of both drugs in phantom limb
pain [10].
Co-codamol was still one of the five most commonly
prescribed first-line treatments in post-herpetic neuralgia
and painful diabetic neuropathy and co-dydramol (para-
cetamol and dihydrocodeine) in post-herpetic neuralgia.
While neither of these options is generally recommended
as a first line treatment [10] it is not unusual to try con-
ventional analgesics before moving to antidepressants and
antiepileptics. The frequent prescription of capsaicin as a
first-line treatment for post-herpetic neuropathy (un-
changed since 2002–5) is not consistent with current evi-
dence although it is recommended as a second line
therapy in the EFNS 2010 guidelines [10].
The analysis of treatments in more than 100 patients
showed that the most commonly prescribed daily doses
for amitriptyline and pregabalin were those recommended
by NICE (10 mg and 150 mg per day respectively) while
higher dosage regimens were not uncommon. EFNS rec-
ommends a higher daily dose of tricyclic antidepressants(25–150 mg/day) and their suggested dose of gabapentin
(1200–3600 mg/day) was prescribed first-line to a minor-
ity of the post-herpetic neuralgia and painful diabetic
neuropathy cohorts. The analysis of pregabalin dosage
regimen did not show a shift from a three to twice a day
dosing although this has been suggested as a cost saving
exercise. The majority of patients were prescribed one
item as a first prescription and one therapeutic category.
This is in-line with current guidance although there is
some evidence that less than half of patients achieve sig-
nificant benefit with any single treatment and that com-
bined treatment may be more effective [23]. Patients who
received more than one therapeutic category usually re-
ceived a mixture of an opioid and a non-opioid analgesic
rather than combinations with demonstrated efficacy in
neuropathic pain, such as gabapentin and opioids or nor-
triptyline [10]. The proportion of patients who received
first-line combination therapy had decreased since the last
analysis for post-herpetic neuralgia (44% to 35%), painful
diabetic neuropathy cohort (36% to 18%) and phantom
limb pain (47% to 27%). Most treatment regimens (mono-
therapy and combination therapy) were prescribed at first-
line (Additional file 2). This may simply be because many
patients did not progress to subsequent/later-line therapy.
Neuropathic back pain and post-operative pain
The inclusion of neuropathic back pain and post-
operative pain was considered exploratory, because these
are less well defined than the other study conditions
with no specific Read code to simplify recording by the
GP. The initial strategy for identifying post-operative
pain involved identifying records with a code for surgery
followed by a record of post-operative pain, plus any
marker that this was neuropathic. When few cases were
identified, the search focused on breast and hernia sur-
gery, which are associated with post-operative pain
[13,24]. The case definition was broadened to include
those with a code for surgery followed by a record of
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apy entries indicative of neuropathic pain. Only 49 pa-
tients were identified despite the use of a wide case
definition. The low patient numbers might partially be
due to our method of case selection, for example we
would have missed cases if the GP recorded ‘pain’ and
used free text to indicate the post-operative or neuro-
pathic nature of that pain. It is also possible that there is
under-diagnosis of post-operative pain in primary care
or that previous studies have over-ascertained significant
long-term post-operative pain. This area therefore war-
rants additional research.
Neuropathic back pain within the study definition in-
creased over the study period from 49 to 62 per 10,000
patient-years. This cannot be considered to be a true in-
cidence because, without a specific code for neuropathic
back pain, the study definition lacked specificity. For ex-
ample, patients with back pain or radiculopathy treated
with tramadol would have been included in the analysis
although tramadol is often also used in nociceptive, ra-
ther than neuropathic pain. Conversely patients with
neuropathic back pain but without a neuropathic code
and treated with opioid/non-opioid combinations would
not have been identified. Additionally, radicular back
pain is not always considered to be neuropathic. The
prescribing patterns in the neuropathic back pain cohort
differed from the other pain conditions, with tramadol
the most frequent first-line therapy and other opioid/
non-opioid analgesics commonly prescribed. This may
be because of co-existing nociceptive pain for which
tramadol efficacy is established [10,25] or indicate
that cases of purely nociceptive pain were included in
the cohort.
Strengths and limitations
This study was based solely on primary care records,
which provides a picture of routine treatment but has a
number of resultant limitations. In particular, not all
cases of post-herpetic neuralgia, painful diabetic neur-
opathy and phantom limb pain were identified using
specific disease codes. The incidence of painful diabetic
neuropathy is considered a maximum rate as the study
definition will include diabetic patients with neuropathic
pain which is not related to diabetes or non-painful
neuropathy if this was diagnosed at the same time as the
patient started a neuropathic pain therapy but for a dif-
ferent indication. The rates of disease we report are
those recorded by the GP so any pain not reported to
the GP will not be included. Additionally, treatments for
pain other than neuropathic pain will have been in-
cluded in the treatment analysis if they were started at
the time of the first neuropathic pain record. More than
a third of patients with neuropathic pain are known to
have other chronic pain-related disease [26]. We couldnot identify a first-line therapy for a number of patients
possibly because treatment started before a diagnosis
was made (phantom limb pain case definition included
a record of neuropathic pain at least 3 months after
amputation), over the counter medications were used,
anti-epileptic treatments used in patients with epilepsy,
treatments such as non-steroidal anti-inflammatory drugs
were prescribed or when the patients did not require or
want a prescription treatment. The validation question-
naire was sent to a small sample and, while the response
rate was good, we have no data on the quality of the re-
sponse and some bias is possible. For example, a record of
a working rather than final diagnoses, or inconsistencies
between the questionnaire and notes, may affect the likeli-
hood of a reply.Conclusion
While treatment for many patients with the neuropathic
pain conditions complied with guidelines available at
that time, this prescribing was often inconsistent with
published evidence of efficacy which is now incorporated
into updated guidelines. Use of antiepileptics with dem-
onstrated efficacy as first-line therapy has increased. Un-
like post-herpetic neuralgia, painful diabetic neuropathy
is difficult to identify from primary care coded records
alone, which has implications for future attempts to es-
tablish incidence using this method. Few cases of post-
operative pain were identified and further research is
needed to understand whether this is due to low rates of
diagnosis, identification or if published rates include
mild intermittent pain.Additional files
Additional file 1: First-, second-, or third-line treatment for
therapies prescribed to more than 100 patients by neuropathic
pain condition; n (% with this therapy and dose included in this
treatment regimen).
Additional file 2: Drugs used in the identification of cases of
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